Robbie McLaren

  • Partner
  • Erobbie.mclaren@lw.com
  • 99 Bishopsgate
  • London EC2M 3XF
  • United Kingdom
  • T +44.20.7710.1880
  •  
 

Profile

Robbie McLaren is a partner in the London office of Latham & Watkins, and serves as Global Vice Chair of the firm’s Healthcare & Life Sciences Industry Group and Co-Chair of the London Corporate Department. He primarily handles cross-border M&A, joint ventures, venture capital, reorganizations, and general corporate matters. Mr. McLaren has represented clients who operate in a number of industries, with a particular focus on clients in the life sciences, healthcare, and technology industries.

 

Experience

Mr. McLaren's experience includes advising:
Life Sciences and Healthcare
  • Abcam, a global leader in the supply of life science research tools:
    • On its US$340 million acquisition of BioVision
    • In regards to its license and asset purchase agreement with Roche Tissue Diagnostics to obtain exclusive rights to the product portfolio of Spring Bioscience Corporation (Spring)
  • BC Partners on the acquisition of a majority interest in the complex generic medicines business of Synthon International, a Netherlands-based multinational pharmaceutical company
  • Atnahs Pharma on its acquisition of assets related to five hypertension medicine brands from AstraZeneca
  • Acino on its acquisition of various pharmaceutical products and related assets in the NEMEA region from Takeda
  • Apotex on the sale of two pharmaceutical products to Intas which are aimed at stimulating white blood cells during chemotherapy
  • 8VC on the sale of their shares in Digital Surgery to Medtronic
  • Baxter International Inc., in connection with its US$625 million acquisition of Claris Injectables Limited, an India-based manufacturer of sterile injectables
  • Sienna Biopharmaceuticals in connection with its acquisition of Creabilis plc, a privately held specialty pharmaceutical company
  • An Asian investor on their investment into Aerogen, an acute aerosol drug delivery business   
  • The shareholders of Pharmathen SA, a Greek pharmaceuticals company, on their sale of a controlling interest in Pharmathen to BC Partners
  • Zogenix on its acquisition of Brabant Pharma, a UK-based pharmaceutical company
  • Novo A/S in:
    • Its £230 million disposal of Archimedes
    • Its US$800 million acquisition of Xellia
    • Its £400 million acquisition of BBI
    • Connection with the initial public offering of ADS on Nasdaq of Freeline Therapeutics
  • Watson Pharmaceuticals / Actavis / Allergan on its:
    • €4.25 billion acquisition of the Actavis Group, making Watson the third largest global generics company
    • Divestment of part of its Western European generics sale and marketing business to Aurobindo
    • US$40.5 billion sale of its global generics pharmaceuticals business to Teva
  • Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with its:
    • US$703 million acquisition by CVC Capital Partners of women’s healthcare assets from Teva Pharmaceutical Industries Ltd
    • Acquisition of certain pharmaceutical products from Janssen
Technology, Media, and Telecoms
  • Bloom & Wild on its acquisition of Bergamotte, a French online florist
  • Darktrace plc in connection with its £1.7 billion initial public offering and listing on the London Stock Exchange
  • The underwriters in connection with the £7.59 billion IPO of Deliveroo Holdings plc, listed on the London Stock Exchange
  • Vertical Aerospace on its US$2.2 billion business combination with Broadstone Acquisition Corp., a special purpose acquisition company
  • Centricus Acquisition Corp, a special purpose acquisition company, on its US$1 billion business combination with Arqit, a London-based developer of a quantum encryption platform
  • Canva, an Australia-based online graphic design and publishing company, on its acquisition of Kiln Enterprises, a data visualization company
  • Impact Holdings, Inc. on its acquisition of Trackonomics, a data management and digital marketing company
  • Mimecast on the acquisition of Simply Migrate, a London-based provider of archive data migration technology
  • Sony Pictures Entertainment and its subsidiary, Columbia Pictures Corporation, on the acquisition of Silvergate Media, a developer of children’s brands for broadcasters, streaming platforms, and retail partners (including the Octonauts, Peter Rabbit, and Hilda animated series)
  • Selina on their equity financings, including its US$125m Series C financing 
  • Hyundai on its investment into AppyParking, a company providing parking apps and services for drivers
  • An Asian investor on their equity investment in:
    • Sound Cloud, a Germany-based company engaged in providing online audio platform services
    • Claroty, a cybersecurity software company
    • Common Sense Robotics
  • Telenor on its €2.8 billion sale of its assets in Central and Eastern Europe (CEE) to PPF Group
  • Kite Tech, a UK-based mobile e-commerce platform specializing in personalized print on its sale to Canon Europa
  • Netflix Inc. on the acquisition of Millarworld, a comic book company founded by Mark Millar
  • Andreessen Horowitz on its minority investment in Improbable World Limited, a UK-based software developer focused on virtual and simulated worlds
  • Intapp on their acquisition of Rekoop
  • The Carlyle Group on its US$400 million investment in Ion Trading and its US$700 million acquisition of Dealogic
  • Calysta on its acquisition of BioProtein A/S    

Thought Leadership

  • Private M&A Market Study, Eighth Edition -  November 16, 2021
  • Digital Health 2021 -  May 27, 2021
  • FCA Consults on Rule Changes to Accommodate SPACs -  May 05, 2021
  • Corporate Reorganisations 2021 -  April 08, 2021
  • IFLR M&A Report 2021 -  March 17, 2021
  • PE Views: Insights on the World of Private Equity -  December 16, 2020
  • Private M&A Market Study, Seventh Edition -  September 28, 2020
  • Focus on Culture and Conduct Brings New Considerations for Corporates and Investors -  June 16, 2020
  • Culture and Conduct Ahead of Exit — Key Points for Private Equity -  June 15, 2020
  • UK Announces Full Details of Future Fund Scheme to Support Startups in COVID-19 Era -  May 19, 2020
  • UK Announces New Funds to Support Startups in the COVID-19 Era -  April 21, 2020
  • Minimising and Mitigating Risk in M&A — Trusted Tools and New Solutions -  February 27, 2020
  • Corporate Reorganisations 2019 -  June 05, 2019
  • Time to Prepare for New EU Medical Device Regime -  May 24, 2019
  • MHRA Releases No-Deal Brexit Guidance for Life Sciences Companies -  April 04, 2019
  • How A No-Deal Brexit Would Affect Life Sciences Cos. -  January 16, 2019
  • Pharma and Biotech: Key Trends and Legal Risks -  November 14, 2017
  • M&A Deal Terms in 2017: What Can Deal Teams Expect? -  May 11, 2017

Clients say that he is a “pharmaceuticals sector expert.”

The Legal 500 2018
Bar Qualification
  • England and Wales (Solicitor)
  • Scotland (Solicitor)
Education
  • Diploma in Legal Practice, University of Edinburgh, 2004
  • LLB (Hons), University of Edinburgh, 2003
Industries
  • Fintech
  • Healthcare & Life Sciences
  • Technology
Languages
  • English
Practices
  • Public Company Representation
  • Mergers & Acquisitions
  • Emerging Companies
  • Private Equity